Last 12 months
Inside the activity.
0 purchase rows · 40 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 0 | 4 |
| Dec 2025 | 0 | 4 |
| Jan 2026 | 0 | 2 |
| Feb 2026 | 0 | 0 |
| Mar 2026 | 0 | 0 |
| Apr 2026 | 0 | 0 |
| May 2026 | 0 | 6 |
| Jun 2026 | 0 | 15 |
| Jul 2026 | 0 | 6 |
| Aug 2026 | 0 | 0 |
| Sep 2026 | 0 | 3 |
| Oct 2026 | 0 | 0 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 06, 2020 Filed Feb 7, 2020 23:50 UTC |
Grigoriadis Dimitri E.Chief Research Officer
|
GrantStock Option · Derivative | 49,844 | $0.00 Strike: $102.90 | $0.00 |
DisclosureSEC source: 0001209191-20-007691 · doc4.xml · derivative · entry 4 Grigoriadis Dimitri E. · CIK 0001423838 · Chief Research Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 49,844 Underlying: Common Stock · 49,844 shares Expires 2030-02-06 F7 · derivative.exercise_date: Represents option of which 1/48th of the shares underlying the option becomes vested and exercisable on March 6, 2020 and an additional 1/48th of the shares underlying the option becomes vested and exercisable each month thereafter. Read SEC document |
| February 06, 2020 Filed Feb 7, 2020 23:50 UTC |
Grigoriadis Dimitri E.Chief Research Officer
|
SaleCommon Stock | 803 | $101.44 | $81,456.16 |
DisclosureSEC source: 0001209191-20-007691 · doc4.xml · nonDerivative · entry 3 Grigoriadis Dimitri E. · CIK 0001423838 · Chief Research Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 110,587 F5 · kind: Sale of 803 shares of common stock issued upon vesting of 1,525 restricted stock units on February 6, 2020 to cover payroll and withholding taxes, with the balance of the shares (722) maintained by the Reporting Person; the disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person at least 60 days prior to the transaction date in Box 2 above. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan. F6 · price: Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $99.67 to $103.03. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| February 06, 2020 Filed Feb 7, 2020 23:49 UTC |
ROBERTS EIRYChief Medical Officer
|
GrantRestricted Stock Unit · Derivative | 8,504 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-007688 · doc4.xml · derivative · entry 2 ROBERTS EIRY · CIK 0001727606 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,504 Underlying: Common Stock · 8,504 shares Expires not disclosed F2 · derivative.exercise_price: Each Restricted Stock Unit represents a contingent right to receive one share of the Issuer Common Stock. F3 · derivative.exercise_date: The Restricted Stock Units will vest annually at 1/4 of the units vesting on each of February 6, 2021, February 6, 2022, February 6, 2023, and February 6, 2024. F3 · derivative.expiration_date: The Restricted Stock Units will vest annually at 1/4 of the units vesting on each of February 6, 2021, February 6, 2022, February 6, 2023, and February 6, 2024. Read SEC document |
| February 06, 2020 Filed Feb 7, 2020 23:49 UTC |
ROBERTS EIRYChief Medical Officer
|
GrantStock Option · Derivative | 53,678 | $0.00 Strike: $102.90 | $0.00 |
DisclosureSEC source: 0001209191-20-007688 · doc4.xml · derivative · entry 1 ROBERTS EIRY · CIK 0001727606 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 53,678 Underlying: Common Stock · 53,678 shares Expires 2030-02-06 F1 · derivative.exercise_date: Represents option of which 1/48th of the shares underlying the option becomes vested and exercisable on March 6, 2020 and an additional 1/48th of the shares underlying the option becomes vested and exercisable each month thereafter. Read SEC document |
| February 06, 2020 Filed Feb 7, 2020 23:47 UTC |
Lloyd-Smith MalcolmChief Regulatory Officer
|
GrantRestricted Stock Unit · Derivative | 6,074 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-007686 · doc4.xml · derivative · entry 5 Lloyd-Smith Malcolm · CIK 0001557146 · Chief Regulatory Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,074 Underlying: Common Stock · 6,074 shares Expires not disclosed F8 · derivative.exercise_price: Each Restricted Stock Unit represents a contingent right to receive one share of the Issuer Common Stock. F9 · derivative.exercise_date: The Restricted Stock Units will vest annually at 1/4 of the units vesting on each of February 6, 2021, February 6, 2022, February 6, 2023, and February 6, 2024. F9 · derivative.expiration_date: The Restricted Stock Units will vest annually at 1/4 of the units vesting on each of February 6, 2021, February 6, 2022, February 6, 2023, and February 6, 2024. Read SEC document |
| February 06, 2020 Filed Feb 7, 2020 23:47 UTC |
Lloyd-Smith MalcolmChief Regulatory Officer
|
GrantStock Option · Derivative | 38,342 | $0.00 Strike: $102.90 | $0.00 |
DisclosureSEC source: 0001209191-20-007686 · doc4.xml · derivative · entry 4 Lloyd-Smith Malcolm · CIK 0001557146 · Chief Regulatory Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 38,342 Underlying: Common Stock · 38,342 shares Expires 2030-02-06 F7 · derivative.exercise_date: Represents option of which 1/48th of the shares underlying the option becomes vested and exercisable on March 6, 2020 and an additional 1/48th of the shares underlying the option becomes vested and exercisable each month thereafter. Read SEC document |
| February 06, 2020 Filed Feb 7, 2020 23:47 UTC |
Lloyd-Smith MalcolmChief Regulatory Officer
|
SaleCommon Stock | 1,490 | $101.52 | $151,257.95 |
DisclosureSEC source: 0001209191-20-007686 · doc4.xml · nonDerivative · entry 3 Lloyd-Smith Malcolm · CIK 0001557146 · Chief Regulatory Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,287 F5 · kind: Sale of 1,490 shares of common stock issued upon vesting of 2,650 restricted stock units on February 6, 2020 to cover payroll and withholding taxes, with the balance of the shares (1,160) maintained by the Reporting Person; the disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person at least 60 days prior to the transaction date in Box 2 above. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan. F6 · price: Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $100.12 to $103.01. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| February 06, 2020 Filed Feb 7, 2020 23:46 UTC |
Lippoldt DarinChief Legal Officer
|
GrantRestricted Stock Unit · Derivative | 7,897 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-007683 · doc4.xml · derivative · entry 5 Lippoldt Darin · CIK 0001504783 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,897 Underlying: Common Stock · 7,897 shares Expires not disclosed F8 · derivative.exercise_price: Each Restricted Stock Unit represents a contingent right to receive one share of the Issuer Common Stock. F9 · derivative.exercise_date: The Restricted Stock Units will vest annually at 1/4 of the units vesting on each of February 6, 2021, February 6, 2022, February 6, 2023, and February 6, 2024. F9 · derivative.expiration_date: The Restricted Stock Units will vest annually at 1/4 of the units vesting on each of February 6, 2021, February 6, 2022, February 6, 2023, and February 6, 2024. Read SEC document |
| February 06, 2020 Filed Feb 7, 2020 23:46 UTC |
Lippoldt DarinChief Legal Officer
|
GrantStock Option · Derivative | 49,844 | $0.00 Strike: $102.90 | $0.00 |
DisclosureSEC source: 0001209191-20-007683 · doc4.xml · derivative · entry 4 Lippoldt Darin · CIK 0001504783 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 49,844 Underlying: Common Stock · 49,844 shares Expires 2030-02-06 F7 · derivative.exercise_date: Represents option of which 1/48th of the shares underlying the option becomes vested and exercisable on March 6, 2020 and an additional 1/48th of the shares underlying the option becomes vested and exercisable each month thereafter. Read SEC document |
| February 06, 2020 Filed Feb 7, 2020 23:46 UTC |
Lippoldt DarinChief Legal Officer
|
SaleCommon Stock | 1,198 | $101.47 | $121,555.67 |
DisclosureSEC source: 0001209191-20-007683 · doc4.xml · nonDerivative · entry 3 Lippoldt Darin · CIK 0001504783 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,755 F5 · kind: Sale of 1,198 shares of common stock issued upon vesting of 2,275 restricted stock units on February 6, 2020 to cover payroll and withholding taxes, with the balance of the shares (1,077) maintained by the Reporting Person; the disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person at least 60 days prior to the transaction date in Box 2 above. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan. F6 · price: Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $99.68 to $103.01. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| February 06, 2020 Filed Feb 7, 2020 23:44 UTC |
GORMAN KEVIN CHARLESDirector · Chief Executive Officer
|
GrantRestricted Stock Unit · Derivative | 23,081 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-007681 · doc4.xml · derivative · entry 5 GORMAN KEVIN CHARLES · CIK 0001201096 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,081 Underlying: Common Stock · 23,081 shares Expires not disclosed F8 · derivative.exercise_price: Each Restricted Stock Unit represents a contingent right to receive one share of the Issuer Common Stock. F9 · derivative.exercise_date: The Restricted Stock Units will vest annually at 1/4 of the units vesting on each of February 6, 2021, February 6, 2022, February 6, 2023, and February 6, 2024. F9 · derivative.expiration_date: The Restricted Stock Units will vest annually at 1/4 of the units vesting on each of February 6, 2021, February 6, 2022, February 6, 2023, and February 6, 2024. Read SEC document |
| February 06, 2020 Filed Feb 7, 2020 23:44 UTC |
GORMAN KEVIN CHARLESDirector · Chief Executive Officer
|
GrantStock Option · Derivative | 145,698 | $0.00 Strike: $102.90 | $0.00 |
DisclosureSEC source: 0001209191-20-007681 · doc4.xml · derivative · entry 4 GORMAN KEVIN CHARLES · CIK 0001201096 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 145,698 Underlying: Common Stock · 145,698 shares Expires 2030-02-06 F7 · derivative.exercise_date: Represents option of which 1/48th of the shares underlying the option becomes vested and exercisable on March 6, 2020 and an additional 1/48th of the shares underlying the option becomes vested and exercisable each month thereafter. Read SEC document |
| February 06, 2020 Filed Feb 7, 2020 23:44 UTC |
GORMAN KEVIN CHARLESDirector · Chief Executive Officer
|
SaleCommon Stock | 4,343 | $101.56 | $441,067.70 |
DisclosureSEC source: 0001209191-20-007681 · doc4.xml · nonDerivative · entry 3 GORMAN KEVIN CHARLES · CIK 0001201096 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 429,436 F5 · kind: Sale of 4,343 shares of common stock issued upon vesting of 8,250 restricted stock units on February 6, 2020 to cover payroll and withholding taxes, with the balance of the shares (3,907) maintained by the Reporting Person; the disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person at least 60 days prior to the transaction date in Box 2 above. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan. F6 · price: Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $99.65 to $103.06. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| February 06, 2020 Filed Feb 7, 2020 23:40 UTC |
ABERNETHY MATTChief Financial Officer
|
GrantRestricted Stock Unit · Derivative | 9,719 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-007678 · doc4.xml · derivative · entry 2 ABERNETHY MATT · CIK 0001724097 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,719 Underlying: Common Stock · 9,719 shares Expires not disclosed F2 · derivative.exercise_price: Each Restricted Stock Unit represents a contingent right to receive one share of the Issuer Common Stock. F3 · derivative.exercise_date: The Restricted Stock Units will vest annually at 1/4 of the units vesting on each of February 6, 2021, February 6, 2022, February 6, 2023, and February 6, 2024. F3 · derivative.expiration_date: The Restricted Stock Units will vest annually at 1/4 of the units vesting on each of February 6, 2021, February 6, 2022, February 6, 2023, and February 6, 2024. Read SEC document |
| February 06, 2020 Filed Feb 7, 2020 23:40 UTC |
ABERNETHY MATTChief Financial Officer
|
GrantStock Option · Derivative | 61,347 | $0.00 Strike: $102.90 | $0.00 |
DisclosureSEC source: 0001209191-20-007678 · doc4.xml · derivative · entry 1 ABERNETHY MATT · CIK 0001724097 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 61,347 Underlying: Common Stock · 61,347 shares Expires 2030-02-06 F1 · derivative.exercise_date: Represents option of which 1/48th of the shares underlying the option becomes vested and exercisable on March 6, 2020 and an additional 1/48th of the shares underlying the option becomes vested and exercisable each month thereafter. Read SEC document |
| February 06, 2020 Filed Feb 7, 2020 23:38 UTC |
Cooke JulieChief Human Resources Officer
|
GrantRestricted Stock Unit · Derivative | 4,860 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-007676 · doc4.xml · derivative · entry 3 Cooke Julie · CIK 0001776977 · Chief Human Resources Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,860 Underlying: Common Stock · 4,860 shares Expires not disclosed F4 · derivative.exercise_price: Each Restricted Stock Unit represents a contingent right to receive one share of the Issuer Common Stock. F5 · derivative.exercise_date: The Restricted Stock Units will vest annually at 1/4 of the units vesting on each of February 6, 2021, February 6, 2022, February 6, 2023, and February 6, 2024. F5 · derivative.expiration_date: The Restricted Stock Units will vest annually at 1/4 of the units vesting on each of February 6, 2021, February 6, 2022, February 6, 2023, and February 6, 2024. Read SEC document |
| February 06, 2020 Filed Feb 7, 2020 23:38 UTC |
Cooke JulieChief Human Resources Officer
|
GrantStock Option · Derivative | 30,674 | $0.00 Strike: $102.90 | $0.00 |
DisclosureSEC source: 0001209191-20-007676 · doc4.xml · derivative · entry 2 Cooke Julie · CIK 0001776977 · Chief Human Resources Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,674 Underlying: Common Stock · 30,674 shares Expires 2030-02-06 F3 · derivative.exercise_date: Represents option of which 1/48th of the shares underlying the option becomes vested and exercisable on March 6, 2020 and an additional 1/48th of the shares underlying the option becomes vested and exercisable each month thereafter. Read SEC document |
| February 06, 2020 Filed Feb 7, 2020 23:37 UTC |
Bozigian Haig P.Chief Development Officer
|
GrantRestricted Stock Unit · Derivative | 2,430 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-007674 · doc4.xml · derivative · entry 5 Bozigian Haig P. · CIK 0001423837 · Chief Development Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,430 Underlying: Common Stock · 2,430 shares Expires not disclosed F9 · derivative.exercise_price: Each Restricted Stock Unit represents a contingent right to receive one share of the Issuer Common Stock. F10 · derivative.exercise_date: The Restricted Stock Units vests in full on February 6, 2021. F10 · derivative.expiration_date: The Restricted Stock Units vests in full on February 6, 2021. Read SEC document |
| February 06, 2020 Filed Feb 7, 2020 23:37 UTC |
Bozigian Haig P.Chief Development Officer
|
GrantStock Option · Derivative | 15,337 | $0.00 Strike: $102.90 | $0.00 |
DisclosureSEC source: 0001209191-20-007674 · doc4.xml · derivative · entry 4 Bozigian Haig P. · CIK 0001423837 · Chief Development Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,337 Underlying: Common Stock · 15,337 shares Expires 2030-02-06 F8 · derivative.exercise_date: Represents option which vests in full on February 6, 2021. Read SEC document |
| February 06, 2020 Filed Feb 7, 2020 23:37 UTC |
Bozigian Haig P.Chief Development Officer
|
SaleCommon Stock | 1,395 | $101.56 | $141,670.06 |
DisclosureSEC source: 0001209191-20-007674 · doc4.xml · nonDerivative · entry 3 Bozigian Haig P. · CIK 0001423837 · Chief Development Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 145,180 F6 · kind: Sale of 1,395 shares of common stock issued upon vesting of 2,650 restricted stock units on February 6, 2020 to cover payroll and withholding taxes, with the balance of the shares (1,255) maintained by the Reporting Person; the disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person at least 60 days prior to the transaction date in Box 2 above. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan. F7 · price: Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $100.12 to $103.08. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| February 05, 2020 Filed Feb 7, 2020 23:35 UTC |
BENEVICH ERICChief Commercial Officer
|
SaleCommon Stock | 809 | $102.90 | $83,247.88 |
DisclosureSEC source: 0001209191-20-007671 · doc4.xml · nonDerivative · entry 2 BENEVICH ERIC · CIK 0001643653 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,007 F4 · kind: Sale of 809 shares of common stock issued upon vesting of 1,537 restricted stock units on February 5, 2020 to cover payroll and withholding taxes, with the balance of the shares (728) maintained by the Reporting Person; the disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person at least 60 days prior to the transaction date in Box 2 above. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan. F5 · price: Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $102.18 to $103.79. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| February 05, 2020 Filed Feb 7, 2020 23:35 UTC |
BENEVICH ERICChief Commercial Officer
|
SaleCommon Stock | 1,145 | $103.11 | $118,063.35 |
DisclosureSEC source: 0001209191-20-007671 · doc4.xml · nonDerivative · entry 1 BENEVICH ERIC · CIK 0001643653 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,279 F1 · kind: Sale of 1,145 shares of common stock issued upon vesting of 2,175 restricted stock units on February 5, 2020 to cover payroll and withholding taxes, with the balance of the shares (1,030) maintained by the Reporting Person; the disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person at least 60 days prior to the transaction date in Box 2 above. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan. F2 · price: Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $102.14 to $105.14. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. F3 · balance_after: Includes a total of 339 shares acquired under the Neurocrine Biosciences 2018 Employee Stock Purchase Plan, consisting of 166 shares on February 28, 2019 and 173 shares on August 30, 2019. Read SEC document |
| February 05, 2020 Filed Feb 7, 2020 23:54 UTC |
Gano KyleChief Business Development Off
|
SaleCommon Stock | 1,974 | $103.08 | $203,482.29 |
DisclosureSEC source: 0001209191-20-007695 · doc4.xml · nonDerivative · entry 3 Gano Kyle · CIK 0001567160 · Chief Business Development Off 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 89,614 F6 · kind: Sale of 1,974 shares of common stock issued upon vesting of 3,750 restricted stock units on February 5, 2020 to cover payroll and withholding taxes, with the balance of the shares (1,776) maintained by the Reporting Person; the disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person at least 60 days prior to the transaction date in Box 2 above. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan. F7 · price: Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $101.86 to $105.07. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| February 05, 2020 Filed Feb 7, 2020 23:54 UTC |
Gano KyleChief Business Development Off
|
SaleCommon Stock | 703 | $103.03 | $72,433.39 |
DisclosureSEC source: 0001209191-20-007695 · doc4.xml · nonDerivative · entry 2 Gano Kyle · CIK 0001567160 · Chief Business Development Off 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 87,838 F4 · kind: Sale of 703 shares of common stock issued upon vesting of 1,337 restricted stock units on February 5, 2020 to cover payroll and withholding taxes, with the balance of the shares (634) maintained by the Reporting Person; the disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person at least 60 days prior to the transaction date in Box 2 above. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan. F5 · price: Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $101.90 to $104.13. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| February 05, 2020 Filed Feb 7, 2020 23:54 UTC |
Gano KyleChief Business Development Off
|
SaleCommon Stock | 1,013 | $103.01 | $104,346.29 |
DisclosureSEC source: 0001209191-20-007695 · doc4.xml · nonDerivative · entry 1 Gano Kyle · CIK 0001567160 · Chief Business Development Off 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 87,204 F1 · kind: Sale of 1,013 shares of common stock issued upon vesting of 1,925 restricted stock units on February 5, 2020 to cover payroll and withholding taxes, with the balance of the shares (912) maintained by the Reporting Person; the disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person at least 60 days prior to the transaction date in Box 2 above. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan. F2 · price: Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $102.16 to $105.09. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. F3 · balance_after: Includes a total of 459 shares acquired under the Neurocrine Biosciences 2018 Employee Stock Purchase Plan, consisting of 312 shares on February 28, 2019 and 147 shares on August 30, 2019. Read SEC document |
| February 05, 2020 Filed Feb 7, 2020 23:50 UTC |
Grigoriadis Dimitri E.Chief Research Officer
|
SaleCommon Stock | 605 | $103.15 | $62,405.33 |
DisclosureSEC source: 0001209191-20-007691 · doc4.xml · nonDerivative · entry 2 Grigoriadis Dimitri E. · CIK 0001423838 · Chief Research Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 109,865 F3 · kind: Sale of 605 shares of common stock issued upon vesting of 1,150 restricted stock units on February 5, 2020 to cover payroll and withholding taxes, with the balance of the shares (545) maintained by the Reporting Person; the disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person at least 60 days prior to the transaction date in Box 2 above. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan. F4 · price: Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $101.98 to $104.20. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| February 05, 2020 Filed Feb 7, 2020 23:50 UTC |
Grigoriadis Dimitri E.Chief Research Officer
|
SaleCommon Stock | 1,013 | $103.15 | $104,489.03 |
DisclosureSEC source: 0001209191-20-007691 · doc4.xml · nonDerivative · entry 1 Grigoriadis Dimitri E. · CIK 0001423838 · Chief Research Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 109,320 F1 · kind: Sale of 1,013 shares of common stock issued upon vesting of 1,925 restricted stock units on February 5, 2020 to cover payroll and withholding taxes, with the balance of the shares (912) maintained by the Reporting Person; the disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person at least 60 days prior to the transaction date in Box 2 above. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan. F2 · price: Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $101.90 to $105.04 The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| February 05, 2020 Filed Feb 7, 2020 23:47 UTC |
Lloyd-Smith MalcolmChief Regulatory Officer
|
SaleCommon Stock | 865 | $103.06 | $89,146.47 |
DisclosureSEC source: 0001209191-20-007686 · doc4.xml · nonDerivative · entry 2 Lloyd-Smith Malcolm · CIK 0001557146 · Chief Regulatory Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,127 F3 · kind: Sale of 865 shares of common stock issued upon vesting of 1,537 restricted stock units on February 5, 2020 to cover payroll and withholding taxes, with the balance of the shares (672) maintained by the Reporting Person; the disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person at least 60 days prior to the transaction date in Box 2 above. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan. F4 · price: Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $101.90 to $105.15. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| February 05, 2020 Filed Feb 7, 2020 23:47 UTC |
Lloyd-Smith MalcolmChief Regulatory Officer
|
SaleCommon Stock | 1,083 | $103.03 | $111,586.36 |
DisclosureSEC source: 0001209191-20-007686 · doc4.xml · nonDerivative · entry 1 Lloyd-Smith Malcolm · CIK 0001557146 · Chief Regulatory Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,455 F1 · kind: Sale of 1,083 shares of common stock issued upon vesting of 1,925 restricted stock units on February 5, 2020 to cover payroll and withholding taxes, with the balance of the shares (842) maintained by the Reporting Person; the disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person at least 60 days prior to the transaction date in Box 2 above. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan. F2 · price: Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $101.90 to $105.04. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| February 05, 2020 Filed Feb 7, 2020 23:46 UTC |
Lippoldt DarinChief Legal Officer
|
SaleCommon Stock | 605 | $103.15 | $62,406.54 |
DisclosureSEC source: 0001209191-20-007683 · doc4.xml · nonDerivative · entry 2 Lippoldt Darin · CIK 0001504783 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,678 F3 · kind: Sale of 605 shares of common stock issued upon vesting of 1,150 restricted stock units on February 5, 2020 to cover payroll and withholding taxes, with the balance of the shares (545) maintained by the Reporting Person; the disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person at least 60 days prior to the transaction date in Box 2 above. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan. F4 · price: Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $101.98 to $104.20. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| February 05, 2020 Filed Feb 7, 2020 23:46 UTC |
Lippoldt DarinChief Legal Officer
|
SaleCommon Stock | 1,145 | $102.88 | $117,800.46 |
DisclosureSEC source: 0001209191-20-007683 · doc4.xml · nonDerivative · entry 1 Lippoldt Darin · CIK 0001504783 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,133 F1 · kind: Sale of 1,145 shares of common stock issued upon vesting of 2,175 restricted stock units on February 5, 2020 to cover payroll and withholding taxes, with the balance of the shares (1,030) maintained by the Reporting Person; the disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person at least 60 days prior to the transaction date in Box 2 above. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan. F2 · price: Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $101.95 to $105.04. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| February 05, 2020 Filed Feb 7, 2020 23:44 UTC |
GORMAN KEVIN CHARLESDirector · Chief Executive Officer
|
SaleCommon Stock | 2,422 | $103.09 | $249,692.94 |
DisclosureSEC source: 0001209191-20-007681 · doc4.xml · nonDerivative · entry 2 GORMAN KEVIN CHARLES · CIK 0001201096 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 425,529 F3 · kind: Sale of 2,422 shares of common stock issued upon vesting of 4,600 restricted stock units on February 5, 2020 to cover payroll and withholding taxes, with the balance of the shares (2,178) maintained by the Reporting Person; the disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person at least 60 days prior to the transaction date in Box 2 above. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan. F4 · price: Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $101.86 to $105.46. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| February 05, 2020 Filed Feb 7, 2020 23:44 UTC |
GORMAN KEVIN CHARLESDirector · Chief Executive Officer
|
SaleCommon Stock | 3,027 | $103.08 | $312,032.85 |
DisclosureSEC source: 0001209191-20-007681 · doc4.xml · nonDerivative · entry 1 GORMAN KEVIN CHARLES · CIK 0001201096 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 423,351 F1 · kind: Sale of 3,027 shares of common stock issued upon vesting of 5,750 restricted stock units on February 5, 2020 to cover payroll and withholding taxes, with the balance of the shares (2,723) maintained by the Reporting Person; the disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person at least 60 days prior to the transaction date in Box 2 above. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan. F2 · price: Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $101.88 to $105.19. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| February 05, 2020 Filed Feb 7, 2020 23:38 UTC |
Cooke JulieChief Human Resources Officer
|
SaleCommon Stock | 605 | $103.17 | $62,417.31 |
DisclosureSEC source: 0001209191-20-007676 · doc4.xml · nonDerivative · entry 1 Cooke Julie · CIK 0001776977 · Chief Human Resources Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,821 F1 · kind: Sale of 605 shares of common stock issued upon vesting of 1,150 restricted stock units on February 5, 2020 to cover payroll and withholding taxes, with the balance of the shares (545) maintained by the Reporting Person; the disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person at least 60 days prior to the transaction date in Box 2 above. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan. F2 · price: Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $102.08 to $104.20. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| February 05, 2020 Filed Feb 7, 2020 23:37 UTC |
Bozigian Haig P.Chief Development Officer
|
SaleCommon Stock | 704 | $103.06 | $72,555.86 |
DisclosureSEC source: 0001209191-20-007674 · doc4.xml · nonDerivative · entry 2 Bozigian Haig P. · CIK 0001423837 · Chief Development Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 143,925 F4 · kind: Sale of 704 shares of common stock issued upon vesting of 1,337 restricted stock units on February 5, 2020 to cover payroll and withholding taxes, with the balance of the shares (633) maintained by the Reporting Person; the disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person at least 60 days prior to the transaction date in Box 2 above. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan. F5 · price: Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $101.90 to $104.13. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| February 05, 2020 Filed Feb 7, 2020 23:37 UTC |
Bozigian Haig P.Chief Development Officer
|
SaleCommon Stock | 1,342 | $103.00 | $138,223.05 |
DisclosureSEC source: 0001209191-20-007674 · doc4.xml · nonDerivative · entry 1 Bozigian Haig P. · CIK 0001423837 · Chief Development Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 143,292 F1 · kind: Sale of 1,342 shares of common stock issued upon vesting of 2,550 restricted stock units on February 5, 2020 to cover payroll and withholding taxes, with the balance of the shares (1,208) maintained by the Reporting Person; the disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person at least 60 days prior to the transaction date in Box 2 above. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan. F2 · price: Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $101.85 to $105.19. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. F3 · balance_after: Includes a total of 108 shares acquired under the Neurocrine Biosciences 2018 Employee Stock Purchase Plan on August 30, 2019. Read SEC document |
| February 01, 2020 Filed Feb 4, 2020 21:34 UTC |
Sharp ShaliniDirector
|
GrantNon-Qualified Stock Option · Derivative | 15,000 | $0.00 Strike: $100.08 | $0.00 |
DisclosureSEC source: 0001209191-20-006379 · doc4.xml · derivative · entry 1 Sharp Shalini · CIK 0001377202 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires 2030-02-01 F1 · derivative.exercise_date: Option granted February 1, 2020 and vests in 36 equal monthly installments. Read SEC document |
| January 08, 2020 Filed Jan 10, 2020 21:10 UTC |
ROBERTS EIRYChief Medical Officer
|
SaleCommon Stock | 2,632 | $111.11 | $292,444.94 |
DisclosureSEC source: 0001209191-20-003043 · doc4.xml · nonDerivative · entry 1 ROBERTS EIRY · CIK 0001727606 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,991 F1 · kind: Sale of 2,632 shares of common stock issued upon vesting of 5,000 restricted stock units on January 8, 2020 to cover payroll and withholding taxes, with the balance of the shares (2,368) maintained by the Reporting Person; the disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person at least 60 days prior to the transaction date in Box 2 above. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan. F2 · price: Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $110.04 to $111.70. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. F3 · balance_after: Includes a total of 480 shares acquired under the Neurocrine Biosciences 2018 Employee Stock Purchase Plan, consisting of 274 shares on February 28, 2019 and 206 shares on August 30, 2019. Read SEC document |
| December 02, 2019 Filed Dec 4, 2019 23:06 UTC |
ABERNETHY MATTChief Financial Officer
|
SaleCommon Stock | 1,645 | $116.33 | $191,360.38 |
DisclosureSEC source: 0001209191-19-059146 · doc4.xml · nonDerivative · entry 1 ABERNETHY MATT · CIK 0001724097 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,876 F1 · kind: Sale of 1,645 shares of common stock issued upon vesting of 3,125 restricted stock units on December 2, 2019 to cover payroll and withholding taxes, with the balance of the shares (1,480) maintained by the Reporting Person; the disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person at least 60 days prior to the transaction date in Box 2 above. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan. F2 · price: Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $114.92 to $117.72. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. F3 · balance_after: Includes a total of 449 shares acquired under the Neurocrine Biosciences 2018 Employee Stock Purchase Plan. 329 shares on February 28, 2019 and 120 shares on August 30, 2019. Read SEC document |
| November 18, 2019 Filed Nov 19, 2019 22:37 UTC |
Grigoriadis Dimitri E.Chief Research Officer
|
Exercise / conversionNon-Qualified Stock Option · Derivative | 5,000 | $35.99 Strike: $35.99 | $179,950.00 |
DisclosureSEC source: 0001209191-19-057272 · doc4.xml · derivative · entry 3 Grigoriadis Dimitri E. · CIK 0001423838 · Chief Research Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,830 Underlying: Common Stock · 5,000 shares Expires 2026-02-05 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: Option granted February 05, 2016 and vests monthly over four years. Read SEC document |
| November 18, 2019 Filed Nov 19, 2019 22:37 UTC |
Grigoriadis Dimitri E.Chief Research Officer
|
SaleCommon Stock | 5,000 | $115.98 | $579,900.00 |
DisclosureSEC source: 0001209191-19-057272 · doc4.xml · nonDerivative · entry 2 Grigoriadis Dimitri E. · CIK 0001423838 · Chief Research Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 108,408 F1 · kind: The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person at least 60 days prior to the transaction date in Box 2 above. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan. Read SEC document |
| November 18, 2019 Filed Nov 19, 2019 22:37 UTC |
Grigoriadis Dimitri E.Chief Research Officer
|
Exercise / conversionCommon Stock | 5,000 | $35.99 | $179,950.00 |
DisclosureSEC source: 0001209191-19-057272 · doc4.xml · nonDerivative · entry 1 Grigoriadis Dimitri E. · CIK 0001423838 · Chief Research Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 113,408 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 08, 2019 Filed Nov 13, 2019 21:41 UTC |
LYONS GARY ADirector
|
SaleCommon Stock | 5,000 | $110.00 | $550,000.00 |
DisclosureSEC source: 0001209191-19-056385 · doc4.xml · nonDerivative · entry 1 LYONS GARY A · CIK 0001123343 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 225,697 F1 · kind: The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person at least 60 days prior to the transaction date in Box 2 above. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan. Read SEC document |
| November 08, 2019 Filed Nov 13, 2019 21:36 UTC |
Lippoldt DarinChief Legal Officer
|
Exercise / conversionIncentive Stock Option · Derivative | 3,375 | $32.99 Strike: $32.99 | $111,341.25 |
DisclosureSEC source: 0001209191-19-056381 · doc4.xml · derivative · entry 6 Lippoldt Darin · CIK 0001504783 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 3,375 shares Expires 2025-02-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: Option granted February 3, 2015 and vested monthly over four years. Read SEC document |
| November 08, 2019 Filed Nov 13, 2019 21:36 UTC |
Lippoldt DarinChief Legal Officer
|
Exercise / conversionNon-Qualified Stock Option · Derivative | 6,625 | $32.99 Strike: $32.99 | $218,558.75 |
DisclosureSEC source: 0001209191-19-056381 · doc4.xml · derivative · entry 5 Lippoldt Darin · CIK 0001504783 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 6,625 shares Expires 2025-02-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: Option granted February 3, 2015 and vested monthly over four years. Read SEC document |
| November 08, 2019 Filed Nov 13, 2019 21:36 UTC |
Lippoldt DarinChief Legal Officer
|
SaleCommon Stock | 3,375 | $110.02 | $371,307.38 |
DisclosureSEC source: 0001209191-19-056381 · doc4.xml · nonDerivative · entry 4 Lippoldt Darin · CIK 0001504783 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,103 F1 · kind: The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person at least 60 days prior to the transaction date in Box 2 above. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan. F3 · price: Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $110.01 to $110.04. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| November 08, 2019 Filed Nov 13, 2019 21:36 UTC |
Lippoldt DarinChief Legal Officer
|
Exercise / conversionCommon Stock | 3,375 | $32.99 | $111,341.25 |
DisclosureSEC source: 0001209191-19-056381 · doc4.xml · nonDerivative · entry 3 Lippoldt Darin · CIK 0001504783 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,478 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 08, 2019 Filed Nov 13, 2019 21:36 UTC |
Lippoldt DarinChief Legal Officer
|
SaleCommon Stock | 6,625 | $110.00 | $728,750.00 |
DisclosureSEC source: 0001209191-19-056381 · doc4.xml · nonDerivative · entry 2 Lippoldt Darin · CIK 0001504783 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,103 F1 · kind: The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person at least 60 days prior to the transaction date in Box 2 above. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan. F2 · price: Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $110.00 to $110.01. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| November 08, 2019 Filed Nov 13, 2019 21:36 UTC |
Lippoldt DarinChief Legal Officer
|
Exercise / conversionCommon Stock | 6,625 | $32.99 | $218,558.75 |
DisclosureSEC source: 0001209191-19-056381 · doc4.xml · nonDerivative · entry 1 Lippoldt Darin · CIK 0001504783 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,728 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 01, 2019 Filed Nov 5, 2019 21:38 UTC |
LYONS GARY ADirector
|
SaleCommon Stock | 5,000 | $100.22 | $501,103.50 |
DisclosureSEC source: 0001209191-19-055235 · doc4.xml · nonDerivative · entry 1 LYONS GARY A · CIK 0001123343 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 230,697 F1 · kind: The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person at least 60 days prior to the transaction date in Box 2 above. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan. F2 · price: Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $100.00 to $100.70. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.